Esperion Therapeutics Inc

Esperion Therapeutics Q1 2026: $25 M net loss improves, modest revenue rise, and key mergers with Corstasis and Essence hint at future growth and stronger market positioning.

Esperion Therapeutics faces market volatility while eyeing the booming PCSK9 arena—explore how its oral, small‑molecule LDL‑lowering strategy could reshape investor expectations and partnership opportunities.

Esperion Therapeutics (ESPR) is a biotech leader developing oral therapies to lower LDL‑cholesterol, with a bullish 52‑week high at $4.18 and a $942 M market cap, positioning it as a top choice for investors in cardiovascular treatment innovation.

Esperion Therapeutics’ oral lipid‑lowering pipeline targets the booming $57 B hypercholesterolemia market, offering cost‑effective, next‑generation cholesterol therapy that could reshape cardiovascular care.

Esperion Therapeutics sees a surge in options trading amid a rebound from $0.69 to $3.95, prompting investors to watch its cardio‑metabolic drug pipeline and future growth prospects.

Esperion Therapeutics reported strong Q2 financial results, exceeding earnings expectations and revenue forecasts, positioning the company for continued growth and success in the healthcare industry.